美股市场个股详情

WNC Wabash国立

添加自选

23.060
-0.220-0.95%

收盘价 05/13 16:00 (美东)

23.350
+0.290+1.26%

盘后 16:31 (美东)

10.38亿总市值5.54市盈率TTM

Wabash国立股票讨论区

登录发表评论

Moomoo AI

02/15 15:36

Wabash's balance sheet strength and strong free cash flow generation are reflected in the increased share repurchase authorization. The company maintains a disciplined capital allocation strategy, balancing business growth investment with shareholder capital return.

Press Release: Wabash Announces Additional $150 Million Increase to Stock Repurchase Authorization

Moomoo AI

01/28 07:09

Wabash National's low P/E ratio may be due to investors expecting its earnings to fall in line with other companies. If profitability doesn't improve, the P/E could drop further. Shareholders accept the current low P/E, expecting no pleasant surprises in future earnings.

Wabash National Corporation's (NYSE:WNC) Shares Lagging The Market But So Is The Business

Moomoo AI

2023/11/15 11:00

Wabash National's increasing ROCE along with stable capital employment indicate heightened efficiency. The 63% return for the stockholders in the previous five years illustrates the positive changes are being acknowledged.

Under The Bonnet, Wabash National's (NYSE:WNC) Returns Look Impressive

Mett

2023/02/14 09:07

$Wabash国立(WNC.US)$
Long/swing $WNC @ 27.94
SL if 15m bar closes below 26.95

BEAN8444

2022/10/31 10:49

Weed Legalization

$Wabash国立(WNC.US)$ https://www.moomoo.com/news/post/16203411/shares-of-cannabis-companies-are-trading-higher-after-senate-majority-leader-schumer-said-congress-is--very-close--to-passing-a-marijuana-banking-and-expungements-bill-?src=2&futusource=news_stock_stockpagenews&re

Moomoo Breakfast US

2022/05/19 07:15

专栏Today's pre-market stock movers: GOOS, TSLA, KSS, UAA and more

Gainers:
• $Rocket Pharmaceuticals(RCKT.US)$ +10.5% (Presents Positive Top-line Data from Severe Leukocyte Adhesion Deficiency-I Program at the 25th Annual Meeting of the American Society of Gene and Cell Therapy)
• $加拿大鹅(GOOS.US)$ +9.4% (the company reported an unexpected profit as well as better-than-expected revenue)
• $SIGA Technologies(SIGA.US)$ +6.4% (FDA approves Intravenous (IV) Formulation of TPOXX (tecovirimat) for t...

暂无评论

分析

分析师评级

暂无数据

目标价预测

暂无数据

热议

美股

综合热度